Eikon Therapeutics, Inc.
EIKNNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-12A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Phase 1/2Recruitingreadout ~2027-06-01A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
- Phase 1/2Recruitingreadout ~2028-12A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- Phase 1/2Recruitingreadout ~2029-03EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Phase 2/3Recruitingreadout ~2035-12Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Phase 2/3Recruitingreadout ~2035-12-31A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Innovation Endeavors Iii LpPassive (13G)May 15, 2026
- Perlmutter Roger MPassive (13G)May 13, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Blackrock Portfolio Management LlcPassive (13G)Apr 29, 2026
- Abu Dhabi Investment AuthorityPassive (13G)Feb 18, 2026
- Column Group Iv Gp, LpActivist (13D)Feb 12, 2026
- Foresite Capital Fund Iv, L.P.Passive (13G)Feb 11, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.6M | 10.4 | +6.6% |
| Apr 30, 2026 | 3.4M | 18.7 | -4.9% |
| Apr 15, 2026 | 3.6M | 9.6 | +7.4% |
| Mar 31, 2026 | 3.3M | 7.0 | +53.0% |
| Mar 13, 2026 | 2.2M | 6.6 | +36.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventJun 1, 2026
- Results of operations · Regulation FD disclosureMay 11, 2026
- Results of operationsMar 30, 2026
- Amended charter or bylawsFeb 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KJun 1, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13GMay 13, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- SCHEDULE 13GMay 6, 2026
- SCHEDULE 13GApr 29, 2026
- 8-KMar 30, 2026
- 10-KMar 30, 2026
- 4Mar 4, 2026
- 4Mar 4, 2026
- 4Mar 4, 2026
- 4Mar 4, 2026
- 4Mar 4, 2026
- 4Mar 4, 2026